Level Biotechnology Inc. (TPEX:3118)
Taiwan · Delayed Price · Currency is TWD 31.75
+0.10 (0.32%)
Aug 4, 2026, 1:30 PM CST
Level Biotechnology Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,030 | 1,071 | 1,038 | 988 | 897 | 972 | |
Market Cap Growth | -1.40% | 3.13% | 5.09% | 10.13% | -7.68% | 0% |
Enterprise Value | 815 | 893 | 662 | 575 | 493 | 578 |
Last Close Price | 31.75 | 30.85 | 28.33 | 25.69 | 22.08 | 22.42 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 13.45 | 13.44 | 16.02 | 15.71 | 15.35 | 14.26 |
PS Ratio | 1.43 | 1.45 | 1.42 | 1.50 | 1.51 | 1.44 |
PB Ratio | 1.72 | 1.85 | 1.86 | 1.80 | 1.65 | 1.78 |
P/TBV Ratio | 1.72 | 1.85 | 1.86 | 1.80 | 1.65 | 1.78 |
P/FCF Ratio | 30.76 | 39.75 | - | 15.80 | 15.38 | 6.62 |
P/OCF Ratio | 16.13 | 17.97 | 16.20 | 14.08 | 13.79 | 6.23 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.13 | 1.21 | 0.91 | 0.87 | 0.83 | 0.85 |
EV/EBITDA Ratio | 7.28 | 8.90 | 7.27 | 6.91 | 6.10 | 6.08 |
EV/EBIT Ratio | 9.12 | 10.69 | 8.79 | 8.51 | 7.59 | 7.32 |
EV/FCF Ratio | 24.33 | 33.16 | - | 9.19 | 8.45 | 3.94 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 |
Debt / EBITDA Ratio | 0.07 | 0.08 | 0.13 | 0.15 | 0.15 | 0.13 |
Debt / FCF Ratio | 0.24 | 0.30 | - | 0.21 | 0.22 | 0.09 |
Net Debt / Equity Ratio | -0.36 | -0.35 | -0.43 | -0.83 | -0.83 | -0.84 |
Net Debt / EBITDA Ratio | -2.03 | -2.01 | -2.64 | -5.46 | -5.59 | -4.83 |
Net Debt / FCF Ratio | -6.43 | -7.51 | 1.51 | -7.26 | -7.73 | -3.13 |
Asset Turnover | 0.87 | 0.87 | 0.89 | 0.81 | 0.74 | 0.87 |
Inventory Turnover | 4.64 | 4.48 | 5.29 | 5.43 | 6.01 | 7.43 |
Quick Ratio | 1.57 | 1.36 | 1.46 | 2.30 | 2.29 | 2.54 |
Current Ratio | 2.11 | 1.82 | 1.92 | 2.69 | 2.62 | 2.82 |
Return on Equity (ROE) | 13.11% | 13.98% | 11.68% | 11.52% | 10.76% | 12.69% |
Return on Assets (ROA) | 6.73% | 6.17% | 5.71% | 5.16% | 5.07% | 6.33% |
Return on Invested Capital (ROIC) | 18.89% | 19.56% | 28.98% | 57.80% | 58.76% | 50.73% |
Return on Capital Employed (ROCE) | 14.70% | 14.10% | 13.10% | 11.90% | 11.60% | 14.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 7.49% | 7.44% | 6.24% | 6.37% | 6.52% | 7.02% |
FCF Yield | 3.25% | 2.51% | -15.37% | 6.33% | 6.50% | 15.10% |
Dividend Yield | 6.95% | 7.13% | 6.35% | 6.62% | 7.70% | 8.48% |
Payout Ratio | 75.72% | 73.30% | 85.12% | 87.70% | 105.46% | 76.16% |
Buyback Yield / Dilution | -0.11% | -0.07% | 0.02% | 0.04% | -0.01% | -0.19% |
Total Shareholder Return | 6.84% | 7.06% | 6.38% | 6.65% | 7.69% | 8.29% |